Pulmonary · PANCE / PANRE

Chronic Obstructive Pulmonary Disease (COPD)

Progressive, largely irreversible airflow limitation from chronic bronchitis and/or emphysema.

Also known as: COPD, emphysema, chronic bronchitis, AECOPD, chronic obstructive lung disease

Overview

Heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum, exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive airflow obstruction (post-bronchodilator FEV1/FVC <0.7).

Epidemiology

Third leading cause of death worldwide. ~16 million diagnosed in the US; many more undiagnosed. Smoking accounts for ~80% of cases in high-income countries; biomass fuel exposure dominates in low-income settings.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Chronic Obstructive Pulmonary Disease (COPD) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Tobacco smoking (current or former) — dose-dependent
Occupational dust/fume exposure (mining, welding, textile, agriculture)
Biomass fuel (wood, coal) indoor smoke
Alpha-1 antitrypsin deficiency (especially <45 years, basal-predominant emphysema, non-smoker)
Childhood respiratory infections, low birth weight (impaired lung growth)
Air pollution

Pathophysiology

Inhaled noxious particles trigger chronic neutrophilic and macrophage-mediated inflammation, oxidative stress, and protease-antiprotease imbalance. Resulting damage: small-airway fibrosis (chronic bronchitis/obliterative bronchiolitis) and alveolar wall destruction (emphysema) → loss of elastic recoil, air trapping, hyperinflation, V/Q mismatch.

Clinical presentation

Symptoms

Chronic productive cough (chronic bronchitis: ≥3 months/year × 2 years)
Progressive exertional dyspnea (mMRC scale)
Wheezing, chest tightness
Frequent respiratory infections, exacerbations

Signs / physical exam

Barrel chest, hyperresonance to percussion, decreased breath sounds, prolonged expiration
Pursed-lip breathing, tripod position, use of accessory muscles
'Pink puffer' (emphysema-predominant): thin, tachypneic, lips pursed
'Blue bloater' (bronchitis-predominant): cyanotic, edematous, productive cough
Signs of cor pulmonale: JVD, peripheral edema, hepatomegaly

Classic findings

Hoover sign (paradoxical inward movement of lower ribs on inspiration), 'tripod' posture, prolonged expiration.

Differential diagnosis

Asthma — Younger onset, atopic history, reversible obstruction (>12% and 200 mL post-bronchodilator), symptom-free between episodes
Bronchiectasis — Copious purulent sputum, recurrent infections, tram-track and signet-ring opacities on HRCT
Heart failure — Orthopnea, PND, elevated BNP, cardiomegaly with pulmonary edema; restrictive (not obstructive) pattern on PFTs
Tuberculosis — Constitutional symptoms, hemoptysis, upper-lobe cavitary disease, positive IGRA/sputum AFB
Idiopathic pulmonary fibrosis — Restrictive pattern on PFTs, dry cough, bibasilar Velcro crackles, honeycombing on HRCT
Alpha-1 antitrypsin deficiency — Premature emphysema (<45 years), basal-predominant on CT, family history; serum AAT level <11 µM
Constrictive (obliterative) bronchiolitis — Post-transplant, post-viral, or connective tissue disease; mosaic attenuation on expiratory CT

Diagnostic workup

Diagnostic criteria

GOLD 2024: symptoms + risk factor exposure + post-bronchodilator FEV1/FVC <0.7. Severity by FEV1 % predicted; clinical group (E, A, B) by symptoms (mMRC, CAT) and exacerbation history.

Labs

Alpha-1 antitrypsin level (once per lifetime, all COPD patients per GOLD)
ABG if severe disease or exacerbation (hypoxia, hypercapnia)
CBC (polycythemia from chronic hypoxia; eosinophilia ≥300 informs ICS use)

Imaging

CXR — hyperinflation (flattened diaphragms, >9 posterior ribs visible), increased AP diameter, bullae
CT chest — emphysema pattern (centrilobular, panlobular, paraseptal), exclude lung cancer; required for lung volume reduction or transplant evaluation
ECG — right axis deviation, P pulmonale, multifocal atrial tachycardia

Other studies

Spirometry (REQUIRED for diagnosis): post-bronchodilator FEV1/FVC <0.7 confirms persistent airflow obstruction
GOLD severity by FEV1 % predicted: GOLD 1 ≥80%, GOLD 2 50-79%, GOLD 3 30-49%, GOLD 4 <30%
6-minute walk test, DLCO (reduced in emphysema)

Diagnostic algorithm

flowchart TD
  A[Suspect COPD<br/>dyspnea, cough, risk factors] --> B[Post-bronchodilator<br/>spirometry]
  B --> C{FEV1/FVC<br/>< 0.7?}
  C -->|No| D[Consider alternative<br/>diagnosis]
  C -->|Yes| E[COPD confirmed]
  E --> F[Assess symptoms<br/>mMRC, CAT]
  E --> G[Assess exacerbations<br/>past 12 months]
  F --> H{GOLD Group}
  G --> H
  H -->|Group A| I[SABA/SAMA<br/>or single LA bronchodilator]
  H -->|Group B| J[LABA + LAMA]
  H -->|Group E| K[LABA + LAMA<br/>+ ICS if eos ≥300]

GOLD 2024 diagnosis and initial pharmacologic treatment algorithm.

Treatment

First-line

Smoking cessation — single most important intervention; reduces rate of FEV1 decline
Pulmonary rehabilitation for mMRC ≥2 or after exacerbation
Vaccinations: annual influenza, pneumococcal (PCV20 or PCV15+PPSV23), COVID-19, RSV (age ≥60), Tdap
GOLD Group A (low symptoms, low exacerbation risk): bronchodilator — short- or long-acting
GOLD Group B (high symptoms, low risk): LABA + LAMA combination
GOLD Group E (any exacerbation history): LABA + LAMA; add ICS if blood eosinophils ≥300 or asthma overlap
Long-acting muscarinic antagonist (LAMA): tiotropium, umeclidinium, glycopyrrolate, aclidinium
Long-acting beta-agonist (LABA): salmeterol, formoterol, olodaterol, indacaterol, vilanterol
Inhaled corticosteroid (ICS): fluticasone, budesonide, mometasone (use only in combination, not monotherapy)

Second-line / adjunct

Triple inhaler (ICS-LABA-LAMA) — fluticasone/umeclidinium/vilanterol or budesonide/glycopyrrolate/formoterol — for persistent exacerbations despite dual therapy
Roflumilast (PDE4 inhibitor) for severe chronic bronchitis with frequent exacerbations
Azithromycin 250 mg daily or 500 mg 3×/week for exacerbation prevention in select patients
Long-term oxygen therapy if resting SpO2 ≤88% or PaO2 ≤55 mmHg (or ≤59 with cor pulmonale/erythrocytosis) — proven to reduce mortality
Lung volume reduction surgery or bronchoscopic valves for severe upper-lobe emphysema
Lung transplantation for end-stage disease
Acute exacerbation (AECOPD): nebulized SABA + SAMA (albuterol-ipratropium), prednisone 40 mg × 5 days (REDUCE trial), antibiotics if increased sputum purulence (azithromycin, doxycycline, amoxicillin-clavulanate), controlled oxygen to SpO2 88-92%, NIV (BiPAP) for hypercapnic respiratory failure

Complications

Acute exacerbations (viral, bacterial — H. influenzae, S. pneumoniae, M. catarrhalis; Pseudomonas in severe)
Cor pulmonale, pulmonary hypertension
Spontaneous pneumothorax (bullae rupture)
Lung cancer (shared smoking risk; screen with low-dose CT in eligible)
Cachexia, sarcopenia, osteoporosis
Depression, anxiety

PANCE pearls

Smoking cessation and long-term oxygen (in qualifying patients) are the ONLY interventions proven to reduce mortality in COPD.
Check Alpha-1 antitrypsin level once in every COPD patient per GOLD — especially if <45, non-smoker, or basal-predominant emphysema.
Target SpO2 88-92% in AECOPD — over-oxygenation can worsen hypercapnia by suppressing hypoxic drive and worsening V/Q matching.
BiPAP reduces intubation and mortality in hypercapnic AECOPD; consider when pH <7.35 with hypercapnia.
Blood eosinophil count guides ICS use: ≥300 cells/µL favors ICS addition; <100 predicts no benefit and higher pneumonia risk.

References

GOLD 2024 — Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2024 Report)
REDUCE Trial — Short-Term vs Conventional Glucocorticoid Therapy in AECOPD (Leuppi et al., JAMA 2013)
NETT Trial — National Emphysema Treatment Trial — Lung Volume Reduction Surgery (Fishman et al., NEJM 2003)
NOTT/MRC — Continuous or Nocturnal Oxygen Therapy in Hypoxemic COPD (NOTT, Ann Intern Med 1980; MRC, Lancet 1981)

Practice Pulmonary questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.